NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pheno Therapeutics

Pheno Therapeutics

Private
EdinburghHealthcare & Life Scienceshttps://phenotherapeutics.com/

Last Round

Series A

Feb 18, 2020

Total Funding Raised

$6.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pheno Therapeutics is a biotechnology company that develops remyelinating therapies designed to halt disability progression in demyelinating diseases such as multiple sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

remyelination therapymultiple sclerosissmall molecule therapyGPR17 antagonistclinical-stage biotechdrug discovery platformphenotypic screeningAI drug discoveryneurodegenerative diseasefirst-in-class drugpharma licensinghigh-content imaging

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pheno Therapeutics Comparables

Compare Pheno Therapeutics with similar companies based on industry and business-model similarity.

Pheno Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rewind Therapeutics
86%
Convelo Therapeutics
86%
Myrobalan Therapeutics
85%

Pheno Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 18, 2020

Key People

Founding team and executive leadership

Fraser Murray

Chief Executive Officer

Executive Team

Pheno Therapeutics Investors

Notable investors and investment history

Pheno Therapeutics investors
InvestorRounds
Advent Life SciencesSeries A
LifeArcSeries A
Scottish Investment Bank (Scottish Enterprise)Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 68% MoM, reaching 2.2K.

  • Mar 1, 2026

    Monthly visitors grew 32% MoM, reaching 2.4K.

Pheno Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pheno Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pheno Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdinburgh
Employee Range8
Year Founded2019
Last FundingFeb 18, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.